
Eli Lilly's gene therapy VERVE-102 cuts LDL cholesterol by up to 62% with lasting effects.
Eli Lilly reported positive Phase 1b results for VERVE-102, a gene therapy that permanently silences the PCSK9 gene to reduce LDL cholesterol by up to 62%. The therapy showed sustained effects for up to 18 months and was well-tolerated with no seriou...
